1stOncology™: Cancer Intelligence Service – Page 13120 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

On September 23, 2019 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, reported that the Company will be presenting updated data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual antagonist of adenosine receptors A2aR and A2bR, in a poster display session at the 2019 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting taking place in Barcelona, Spain from September 27-October 1, 2019 (Press release, Arcus Biosciences, SEP 23, 2019, View Source [SID1234539719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Poster presentation details

Title: Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presentation Number: 1206P
Session Name: Poster Display Session
Date and Time: Monday, September 30, 12:00 p.m. – 1:00 p.m. Central European Summer Time (CEST)
Location: Poster Area (Hall 4), Fira Gran Via, Barcelona, Spain

A copy of the poster will be available on the "Publications" section of the Arcus website at www.arcusbio.com.

About AB928

AB928 is a dual antagonist of adenosine receptors A2aR and A2bR designed to block adenosine-mediated impairment of intra-tumoral immune cells, mainly lymphocytes (CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages). Developed specifically for the oncology setting, AB928 achieves high penetration of tumor tissue, robust potency in the presence of high adenosine concentrations, and minimal shift in potency from non-specific protein binding. Among agents in the clinic, AB928 is the only antagonist of A2bR, found on both myeloid cells and cancer cells. AB928 thereby uniquely blocks adenosine’s immunosuppressive and cancer cell-intrinsic effects in the tumor microenvironment. AB928 has demonstrated a favorable safety profile with a variety of combination regimens and exhibits pharmacokinetics / pharmacodynamics consistent with once-daily dosing. AB928 is currently in several ongoing Phase 1/1b expansion trials across multiple indications.

About AB122

AB122 is a fully human IgG4 antibody that potently and selectively blocks PD-1. The biochemical, biological and preclinical properties of AB122 have been shown to be similar to those of marketed anti-PD-1 antibodies. The Company is evaluating AB122 both as monotherapy and in combination as a core component for the Company’s intra-portfolio combinations. AB122 is progressing into a Phase 1b biomarker-selected trial across advanced solid tumors in collaboration with Strata Oncology utilizing Strata’s precision drug development platform and proprietary biomarkers. AB122 is also in Phase 1/1b expansion trials in combination with AB928, a dual antagonist of adenosine receptors A2aR and A2bR, in combination with AB154, its anti-TIGIT antibody, and in combination with AB680, its small-molecule CD73 inhibitor, plus chemotherapy.

Bioasis Announces Proposed Private Placement

On September 23, 2019 BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, reported that it intends to complete a brokered private placement financing (the "Offering") of units (the "Units") for gross proceeds of approximately US$4 million (Press release, biOasis, SEP 23, 2019, View Source [SID1234539718]).

Each Unit will consist of one common share of the company (a "Common Share") and one warrant to purchase one Common Share (a "Warrant") offered at CA$0.225, a 20% discount to the volume weighted average price per share of the company’s common shares on the TSXV over the 20 trading day period ending on September 20, 2019. Each Warrant will have a five year term and an exercise price equal to 120% of the Offering Price.

Boustead Securities, LLC are acting as the placement agent for U.S. investors participating in the Offering on a "best efforts" basis. The Agents will be paid a cash commission equal to 8% of the gross proceeds from the Offering and will also be issued broker warrants to purchase that number of Common Shares equal to 8% of the total number of Units sold in the Offering at a price equal to the Offering Price for a period of three years from the closing date of the Offering.

An initial closing of the Offering is expected to occur on or before September 27, 2019 and is subject to the satisfaction of waiver of certain conditions, including the delivery of definitive subscription agreements and TSX Venture Exchange approval. All the securities issued pursuant to the Offering will be subject to a hold period in Canada expiring four months and a day after the closing date and will be restricted securities for the purposes of United States securities laws.

The company intends to use the net proceeds from the Offering for manufacturing, IND enabling studies, legal expenses (including for patent and other intellectual property work) and for general working capital purposes.

"This financing will provide additional support to Bioasis as we progress xB3-001 as a treatment for HER2+ breast cancer and brain metastases. It follows the positive response we received from the FDA to our recent pre-IND submission and recognizes the strength of the company’s intellectual property covering xB3-001," said executive chair Deborah Rathjen, Ph.D.

"We believe that xB3-001, an xB3-Herceptin construct, may be an effective treatment for HER2+ brain metastases with the potential for accelerated approval," Dr. Rathjen continued. "Herceptin continues to be the backbone of treatment of HER2+ breast cancer despite its lack of brain penetrance. In preclinical animal models xB3-001 has demonstrated a 10-fold increase in brain penetrance and efficacy in the treatment of HER2+ brain tumors."

City of Hope opens chimeric antigen receptor (CAR) T cell trial for advanced prostate cancer

On September 23, 2019 City of Hope reported that it has opened and is treating the first patients in its CAR T cell trial for prostate cancer that has spread to other parts of the body (Press release, City of Hope, SEP 23, 2019, View Source [SID1234539717]). The trial uses a CAR T cell – also developed at City of Hope – that targets the prostate stem cell antigen (PSCA) in prostate cancer.

The trial, which can enroll up to 33 patients, aims to find the appropriate dose of PSCA CAR T cells that a patient should receive and any side effects that the treatment may cause. Researchers will also study the expansion and persistence of the CAR T cells, survival outcomes and other findings.

Patients with PSCA-positive castration-resistant prostate cancer that has metastasized to other areas in the body, and who meet other requirements, are eligible for the trial, which includes the National Cancer Institute as a collaborator.

According to the American Cancer Society (ACS), other than skin cancer, prostate cancer is the most common cancer in American men. The ACS estimates that about 174,650 men will be diagnosed with new cases of prostate cancer and about 31,620 deaths will occur due to prostate cancer.

"Patients with advanced prostate cancer are in urgent need of a therapy that could provide a more durable remission," said Tanya Dorff, M.D., City of Hope associate clinical professor in the Department of Medical Oncology & Therapeutics Research, head of the Genitourinary Cancers Program and the trial’s principal investigator. "CAR T cell therapy has cured some cancers that are difficult to treat, and we want to know if we can do that for prostate cancer. Our hope is that this CAR T cell therapy can be a game changer for these patients."

CAR T cell therapy involves taking a patient’s immune cells, known as T cells, from the bloodstream. They are then reprogrammed in a laboratory to recognize and attack a specific cancer-causing protein, such as PSCA, and reintroduced into the patient’s bloodstream, where they get to work destroying targeted tumor cells.

City of Hope will manufacture the CAR T cells using in its own facility, the Cellular Therapy Production Center. This process includes a critical step: The patient’s T cells are reprogrammed with viruses engineered in another of City of Hope’s GMP facilities, the Center for Biomedicine & Genetics. These two facilities, coupled with its Chemical GMP Synthesis Facility, make City of Hope one of the few cancer centers in the world with the ability to produce GMP cellular, genetic and drug-based therapies for its patients.

City of Hope developed the CAR design in its own laboratory with a goal of finding the most effective and long-lasting CAR T cell to target PSCA.

"Developing a CAR T cell therapy for solid tumors is particularly challenging because they need to first reach the solid tumor and then survive in a harsh microenvironment that is filled with cancer cells and other cells that make up the tumor mass," said Saul Priceman, Ph.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation. "This CAR design has allowed for optimal cytokine production, which are chemical messengers that help enhance the anti-tumor activity of a CAR T cell, and destruction of prostate stem cell antigen (PSCA)-positive prostate cancers by the CAR T cells."

The trial is one of the first CAR T trials for prostate cancer in the nation. Since the late 1990s, City of Hope has been a leader in advancing CAR T cell therapies across a range of blood cancers and, in recent years, it has also opened trials for solid tumors, including brain cancer (glioblastoma) for adults and children, HER2-positive breast cancer that has metastasized to the brain and this prostate cancer trial.

City of Hope patents covering the PSCA CAR have been licensed to Mustang Bio.

City of Hope received a Challenge Award in 2013 from the Prostate Cancer Foundation (PCF) to support the CAR T cell therapy’s preclinical development, and in 2016 from PCF, which was matched by City of Hope, to fund the clinical trial. Research is also supported by a generous gift from Barbara and Zach Horowitz and Gary Marsh and Jody Horowitz Marsh.

The trial is part of City of Hope’s T Cell Therapeutics Research Laboratory, which currently has 20 open CAR T and T cell clinical trials.

Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery

On September 23, 2019 Biodesix, Inc. reported updates on continued expansion of pipeline and companion diagnostic developments. Chief Development Officer Dr. Gary Pestano, Ph.D., highlighted the company’s capabilities in the development and commercialization of companion diagnostics aimed at directing the treatment of non-small cell lung cancer (NSCLC) at the 2019 Clinical Biomarkers & World CDx Conference (Press release, Biodesix, SEP 23, 2019, View Source [SID1234539715]). Director of Scientific & Medical Affairs, Dr. Yishan Chuang, Ph.D., presented real-world data on the importance of monitoring KRAS mutations in blood at the RAS-Targeted Drug Discovery meeting.

Companion Diagnostic Developments

Dr. Pestano cited two case studies of recent projects in CDx development. The first outlined Biodesix’s worldwide agreement to develop and commercialize the hepatocyte growth factor inhibitor antibody ficlatuzumab with Aveo Oncology (AVEO), using Biodesix’s proprietary VeriStrat test as a CDx to identify NSCLC patients most likely to benefit from treatment with ficlatuzumab.

Biodesix’s recent agreement with Thermo Fisher was also presented, highlighting the ability to access a global footprint of instruments with rapid turn-around time and low-input material requirements for a liquid biopsy NGS test. The 52-gene panel is currently under dual track single-site PMA review by the FDA and CMS, with a goal of gaining approval with reimbursement in 2020. The approval will be initially focused on EGFR and NSCLC, with the ability to extend into other targets and indications as new partnerships develop.

"Our ongoing efforts in the discovery, development, and commercialization of companion diagnostic tests alongside our partners in biopharma further demonstrates Biodesix’s commitment to advancing precision medicine," said Pestano. "Companion diagnostics, in addition to Biodesix’s portfolio of proprietary blood-based tests both currently available and in development, are designed to answer critical unmet needs across the continuum of care in oncology, NSCLC, and lung disease."

Monitoring KRAS Mutations in Blood

Dr. Chuang shared data from INSIGHT, an observational study assessing real-world clinical utility of VeriStrat and GeneStrat testing in 3,000 NSCLC patients across 33 sites in the U.S. Results from the INSIGHT study demonstrate poor response to treatment with platinum doublet-based chemotherapy in patients when KRAS mutations are detected in the blood (OS 3.4 months v. 14.0 months, p<0.001). It was noted that the particularly poor prognosis observed in these groups may be linked to tumors that shed DNA into the blood having a more aggressive disease state to those that don’t, highlighting the value of blood-based testing in addition to standard tissue testing. Additionally, longitudinal monitoring of KRAS mutation clearance in the blood may be an important indicator for treatment response. Dr. Chuang also noted that by combing information from both the circulating proteome with the VeriStrat test and circulating genome with GeneStrat testing provides additional value in predicting NSCLC patient prognosis.

"With the exciting development of KRAS targeted therapy in clinical studies, there is an increasing need for swift mutation testing with liquid biopsy," said Dr. Chuang. "From Biodesix’s INSIGHT study, we also see that patient prognosis could be further elucidated when we consider both KRAS mutation information in combination with the circulating proteome in blood."

Tarveda Therapeutics to Present at Upcoming Conferences

On September 23, 2019 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with a wide range of solid tumor malignancies, reported that the company will present results from the Phase 1 portion of a Phase 1/2a study of PEN-866 in patients with advanced solid malignancies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2019, occurring September 27 – October 1, in Barcelona, Spain (Press release, Tarveda Therapeutics, SEP 23, 2019, View Source [SID1234539714]). In addition, Mark Bilodeau, Chief Scientific Officer of Tarveda, will present on payload masking in activated Heat Shock Protein 90 (HSP90) binding miniature drug conjugates at the 10th Annual World ADC, occurring October 8 – 11, in San Diego, California.

At ESMO (Free ESMO Whitepaper), Johanna Bendell will present results from an ongoing Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PEN-866 in patients with progressive, advanced solid malignancies. At the time of this reporting, a number of patients remain on the study, therefore this does not represent the final data set. PEN-866 is a miniature drug conjugate that selectively binds to the activated intracellular target HSP90 and is linked to a topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 is designed to accumulate and be retained in tumors and, by way of a sustained release of SN-38, cause prolonged DNA damage and tumor regressions.

Details of the presentations are as follows:

ESMO Congress 2019
Title: First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) – SN38 conjugate for patients with advanced Solid Malignancies: Phase 1 results.
Date: September 28, 2019
Time: 12:00 PM CEST
Location: Poster Area (Hall 4), Fira Gran Via, Barcelona, Spain

10th Annual World ADC
Title: Payload Masking in HSP90 Targeting Miniature Drug Conjugates to Expand the Therapeutic Window
Date: October 11, 2019
Time: 12:30 PM PT
Location: Manchester Grand Hyatt, San Diego, CA